174 related articles for article (PubMed ID: 32319737)
1. How many chronic myeloid leukemia patients who started a frontline second-generation tyrosine kinase inhibitor have to switch to a second-line treatment? A retrospective analysis from the monitoring registries of the italian medicines agency (AIFA).
Breccia M; Olimpieri PP; Olimpieri O; Pane F; Iurlo A; Foggi P; Cirilli A; Colatrella A; Cuomo M; Gozzo L; Summa V; Corradini P; Russo P;
Cancer Med; 2020 Jun; 9(12):4160-4165. PubMed ID: 32319737
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcome of chronic myeloid leukemia patients who switch from first-line therapy with a second generation tyrosine kinase inhibitor to an alternative TKI.
Ma CE; Ghosh S; Leyshon C; Blosser N; Dersch-Mills D; Jupp J; Savoie L; Liew E; Jamani K
Leuk Res; 2021 Dec; 111():106674. PubMed ID: 34333277
[TBL] [Abstract][Full Text] [Related]
3. Real-world analysis of tyrosine kinase inhibitor treatment patterns among patients with chronic myeloid leukemia in the United States.
Henk HJ; Woloj M; Shapiro M; Whiteley J
Clin Ther; 2015 Jan; 37(1):124-33. PubMed ID: 25467191
[TBL] [Abstract][Full Text] [Related]
4. Third-line treatment with second-generation tyrosine kinase inhibitors (dasatinib or nilotinib) in patients with chronic myeloid leukemia after two prior TKIs: real-life data on a single center experience along with the review of the literature.
Ongoren S; Eskazan AE; Suzan V; Savci S; Erdogan Ozunal I; Berk S; Yalniz FF; Elverdi T; Salihoglu A; Erbilgin Y; Iseri SA; Ar MC; Baslar Z; Aydin Y; Tuzuner N; Ozbek U; Soysal T
Hematology; 2018 May; 23(4):212-220. PubMed ID: 28990873
[TBL] [Abstract][Full Text] [Related]
5. Mortality rate in patients with chronic myeloid leukemia in chronic phase treated with frontline second generation tyrosine kinase inhibitors: a retrospective analysis by the monitoring registries of the Italian Medicines Agency (AIFA).
Breccia M; Celant S; Olimpieri PP; Olimpieri OM; Pane F; Iurlo A; Cirilli A; Colatrella A; Gozzo L; Pugliese S; Summa V; Foggi P; Corradini P; Russo P;
Ann Hematol; 2021 Feb; 100(2):481-485. PubMed ID: 33415425
[TBL] [Abstract][Full Text] [Related]
6. Pattern of Use and Long-Term Safety of Tyrosine Kinase Inhibitors: A Decade of Real-World Management of Chronic Myeloid Leukemia.
Bettiol A; Marconi E; Lombardi N; Crescioli G; Gherlinzoni F; Walley T; Vannacci A; Chinellato A; Giusti P
Clin Drug Investig; 2018 Sep; 38(9):837-844. PubMed ID: 30043130
[TBL] [Abstract][Full Text] [Related]
7. Real-life comparison of nilotinib versus dasatinib as second-line therapy in chronic phase chronic myeloid leukemia patients.
Scalzulli E; Caocci G; Efficace F; Rizzo L; Colafigli G; Di Prima A; Pepe S; Fegatelli DA; Carmosino I; Diverio D; Latagliata R; La Nasa G; Martelli M; Foà R; Breccia M
Ann Hematol; 2021 May; 100(5):1213-1219. PubMed ID: 33677654
[TBL] [Abstract][Full Text] [Related]
8. Real world treatment patterns in chronic myeloid leukemia patients newly initiated on tyrosine kinase inhibitors in an U.S. integrated healthcare system.
Rashid N; Koh HA; Lin KJ; Stwalley B; Felber E
J Oncol Pharm Pract; 2018 Jun; 24(4):253-263. PubMed ID: 29284347
[TBL] [Abstract][Full Text] [Related]
9. Determinants of frontline tyrosine kinase inhibitor choice for patients with chronic-phase chronic myeloid leukemia: A study from the Registro Italiano LMC and Campus CML.
Tiribelli M; Latagliata R; Breccia M; Capodanno I; Miggiano MC; Cavazzini F; Bucelli C; Attolico I; Crescenzi SL; Russo S; Annunziata M; Sorà F; Bonifacio M; Mulas O; Loglisci G; Maggi A; Binotto G; Crisà E; Scortechini AR; Leporace AP; Sancetta R; Murgano P; Abruzzese E; Stagno F; Rapezzi D; Luzi D; Vincelli I; Bocchia M; Fava C; Malato A; Crugnola M; Pizzuti M; Lunghi F; Galimberti S; Dalmazzo M; Fanin R; Scalzulli E; Foà R; Iurlo A; Saglio G; Specchia G
Cancer; 2023 Sep; 129(17):2637-2644. PubMed ID: 37354090
[TBL] [Abstract][Full Text] [Related]
10. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
Ferri C; Bianchini M; Bengió R; Larripa I
Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
[TBL] [Abstract][Full Text] [Related]
11. Does the frequency of molecular monitoring after tyrosine kinase inhibitor discontinuation affect outcomes of patients with chronic myeloid leukemia?
Kong JH; Winton EF; Heffner LT; Chen Z; Langston AA; Hill B; Arellano M; El-Rassi F; Kim A; Jillella A; Kota VK; Bodó I; Khoury HJ
Cancer; 2017 Jul; 123(13):2482-2488. PubMed ID: 28241101
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Long-Term Chronic Myeloid Leukemia Treatment Practices with Tyrosine Kinase Inhibitors in a National Cohort of Veterans.
Kreys ED; Frei CR; Villarreal SM; Bollinger MJ; Jones X; Koeller JM
Pharmacotherapy; 2017 Mar; 37(3):278-286. PubMed ID: 28052354
[TBL] [Abstract][Full Text] [Related]
13. Finding the right BCR-ABL1 tyrosine kinase inhibitor: a case report of successful treatment of a patient with chronic myeloid leukemia and a V299L mutation using nilotinib.
Elnair R; Galal A
BMC Cancer; 2018 Nov; 18(1):1097. PubMed ID: 30419862
[TBL] [Abstract][Full Text] [Related]
14. Selecting the best frontline treatment in chronic myeloid leukemia.
Yilmaz M; Abaza Y; Jabbour E
Curr Hematol Malig Rep; 2015 Jun; 10(2):145-57. PubMed ID: 25921387
[TBL] [Abstract][Full Text] [Related]
15. Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring.
Jabbour E; Kantarjian H
Am J Hematol; 2018 Mar; 93(3):442-459. PubMed ID: 29411417
[TBL] [Abstract][Full Text] [Related]
16. Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring.
Jabbour E; Kantarjian H
Am J Hematol; 2020 Jun; 95(6):691-709. PubMed ID: 32239758
[TBL] [Abstract][Full Text] [Related]
17. Real-life comparison of severe vascular events and other non-hematological complications in patients with chronic myeloid leukemia undergoing second-line nilotinib or dasatinib treatment.
Gora-Tybor J; Medras E; Calbecka M; Kolkowska-Leśniak A; Ponikowska-Szyba E; Robak T; Jamroziak K
Leuk Lymphoma; 2015; 56(8):2309-14. PubMed ID: 25563556
[TBL] [Abstract][Full Text] [Related]
18. Incidence and outcome of second malignancies in patients with chronic myeloid leukemia during treatment with tyrosine kinase inhibitors.
Nakazato T; Iriyama N; Tokuhira M; Ishikawa M; Sato E; Takaku T; Sugimoto KJ; Fujita H; Fujioka I; Kimura Y; Aisa Y; Iwanaga E; Asou N; Kizaki M; Hatta Y; Komatsu N; Kawaguchi T
Med Oncol; 2018 May; 35(7):99. PubMed ID: 29846829
[TBL] [Abstract][Full Text] [Related]
19. Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring.
Jabbour E; Kantarjian H
Am J Hematol; 2016 Feb; 91(2):252-65. PubMed ID: 26799612
[TBL] [Abstract][Full Text] [Related]
20. Long term follow-up of frontline Dasatinib in older patients with chronic myeloid leukemia in chronic phase treated outside clinical trials: a real-life cohort observational study.
Stagno F; Breccia M; Annunziata M; Trawinska MM; Iurlo A; Sgherza N; Fava C; Gozzini A; Luciano L; Carmosino I; Bonifacio M; Sorà F; Leonetti Crescenzi S; Crugnola M; Gugliotta G; Galimberti S; Bucelli C; Colafigli G; Feo C; Tiribelli M; Mauro E; Russo Rossi A; Guarini A; Abruzzese E; Rosti G; Di Raimondo F; Latagliata R
Acta Oncol; 2021 Nov; 60(11):1527-1533. PubMed ID: 34499575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
